Company Overview
Allurion Technologies Inc. is dedicated to the healthcare sector, specifically within the medical devices industry, where it develops a swallowable and procedure-less intragastric balloon designed to treat individuals who are overweight and ends obesity through a specialized weight loss platform. The company's operational scale is defined by a market capitalization of $11.58 million and a trailing twelve-month revenue of $17.21 million, supported by a workforce of 134 employees. These valuation figures indicate that the company operates as a small-cap entity with limited market penetration relative to larger peers in the medical device space. The revenue of $17.21 million suggests a niche product focus rather than broad-scale commercial dominance, while the modest employee count reflects a lean organizational structure typical of early-stage biotechnology and medical device firms.
Financial Health
The company reported a revenue of $17.21 million for the trailing twelve months, yet this generated a net income of -$32,328,000 and an EBITDA of -$38,541,000, revealing a cost structure where operating expenses and research costs significantly exceed gross profit generation. Free cash flow stands at -$18,781,250, which indicates a lack of financial flexibility for organic expansion or capital expenditure without external financing. The gross margin is 61.0%, demonstrating that the core product retains significant value before operating expenses, whereas the operating margin is -362.3% and the profit margin is -187.9%, signaling that overhead and selling, general, and administrative costs are currently destroying value at a rate far exceeding revenue generation. The balance sheet shows cash holdings of $6.14 million against total debt of $83.29 million, creating a situation where the company is heavily leveraged despite the debt-to-equity ratio being listed as N/A due to the negative equity position. The current ratio is 1.26, which suggests the company maintains just enough current assets to cover current liabilities, though the margin of safety is narrow given the high debt load. Return on Equity is N/A because of the negative equity, while Return on Assets is -71.9%, indicating that the asset base is currently generating a substantial negative return relative to its size.
Valuation Assessment
The trailing P/E ratio is N/A due to the reported net losses, while the forward P/E is -1.61, a metric that implies the market is pricing in a continued period of negative earnings rather than a standard growth trajectory. The price-to-book ratio is -0.07, which indicates that the market capitalization is trading at a significant discount to the company's book value, a common characteristic for distressed or loss-making biotechnology companies. Alternative valuation metrics such as the price-to-sales ratio of 0.67 and an EV/EBITDA of -2.19 suggest that investors are valuing the company primarily on its future potential revenue streams rather than current profitability or cash generation. The 52-week high is $3.83 and the 52-week low is $0.23, placing the current trading price at a point that requires specific calculation to determine its exact percentage distance from the high or low, but strictly speaking, the range highlights a massive volatility window of over $3.60. The beta value is -0.46, which is an anomalous metric indicating an inverse relationship to the broader market, suggesting the stock price moves in the opposite direction of the market index with a dampened magnitude.
Growth & Income
Revenue growth year-over-year is -50.5%, while earnings growth is N/A due to the absence of positive earnings, implying that the company is in a contractionary phase regarding top-line sales rather than an expansionary growth phase. For non-dividend payers, the dividend yield is N/A and the payout ratio is 0.0%, meaning the company does not distribute cash to shareholders but instead retains its minimal cash reserves to attempt to fund operations and service its debt obligations. The overall growth and income profile reflects a mature yet distressed phase where the company has stopped paying dividends and is experiencing significant revenue decline, relying entirely on its remaining cash balance and potential future product uptake to stabilize its financial position.